MitoRx Therapeutics are developing first-in-class, mitochondrial-targeted sulfide-donor therapies designed to
• restore cellular energy
• drive fat loss
• protect muscle
They recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·
